Automate Your Wheel Strategy on AMGN
With Tiblio's Option Bot, you can configure your own wheel strategy including AMGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AMGN
- Rev/Share 64.8792
- Book/Share 13.8067
- PB 20.3162
- Debt/Equity 7.5665
- CurrentRatio 1.3056
- ROIC 0.1044
- MktCap 151010541000.0
- FreeCF/Share 19.7119
- PFCF 14.2396
- PE 22.7994
- Debt/Assets 0.6394
- DivYield 0.0335
- ROE 0.9792
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AMGN | Raymond James | -- | Market Perform | -- | -- | Sept. 3, 2025 |
| Resumed | AMGN | Guggenheim | -- | Neutral | -- | $288 | May 20, 2025 |
| Resumed | AMGN | Cantor Fitzgerald | -- | Neutral | -- | $305 | April 22, 2025 |
| Resumed | AMGN | BofA Securities | -- | Underperform | -- | $256 | Dec. 10, 2024 |
| Initiation | AMGN | Bernstein | -- | Outperform | -- | $380 | Oct. 17, 2024 |
| Downgrade | AMGN | Truist | Buy | Hold | $320 | $333 | Oct. 14, 2024 |
| Initiation | AMGN | Cantor Fitzgerald | -- | Overweight | -- | $405 | Sept. 27, 2024 |
News
Amgen Inc. (AMGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Amgen Inc. (NASDAQ:AMGN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 10:15 AM EDT Company Participants Adam Elinoff Paul Burton - Senior VP & Chief Medical Officer Casey Capparelli Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst So we have Paul Burton. He's the Chief Medical Officer of the company; and dabbing for the first time, Adam Elinoff, the new IR at Amgen.
Read More
Investing in the Age of Longevity: Silver Economy Stocks in Focus
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
Read More
Here's Why Amgen (AMGN) is a Strong Value Stock
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Calls of the Day: Micron, DoorDash, Amer Sports, Amgen, Merck and Costco
Published: August 27, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?
Published: August 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.
Read More
REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
Published: August 25, 2025 by: PRNewsWire
Sentiment: Neutral
THOUSAND OAKS, Calif. , Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C), commonly known as 'bad cholesterol.
Read More
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Read More
Back To Basics: Why I Favor Amgen Over Johnson & Johnson
Published: August 14, 2025 by: Seeking Alpha
Sentiment: Positive
Both Amgen (AMGN) and Johnson & Johnson (JNJ) recently received a 60-day ultimatum to lower their prices in the U.S. market. A fundamental analysis shows AMGN to be better positioned than JNJ to absorb drug pricing pressure. Both companies have robust profitability and R&D pipelines, but AMGN's growth record and PEGY ratio make it more appealing under current conditions.
Read More
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Published: August 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys
Published: August 07, 2025 by: Seeking Alpha
Sentiment: Positive
Verizon is the only Dow stock currently meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are supported by free cash flow. Analyst forecasts suggest top Dow dividend stocks could deliver 14.93% to 41.48% net gains by August 2026, with an average estimated gain of 23.33%. Most Dow stocks remain overpriced relative to their dividends, but market pullbacks or dividend increases could bring more into fair-value territory for income investors.
Read More
Amgen Stock Sinks As Market Eyes MariTide's Next Move
Published: August 06, 2025 by: Benzinga
Sentiment: Negative
Amgen Inc. AMGN shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.
Read More
Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen posts strong Q2 beats on earnings and sales, driven by double-digit drug volume gains.
Read More
Trade Deficit Narrowed More Than Expected
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
Pre-market futures are in the green across major indexes this morning, but experiencing a bit of choppiness. The Dow and S&P 500 are both up mere single-digits at this hour, off the early-morning highs, while the tech-heavy Nasdaq stays up +70 points presently.
Read More
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
Read More
Buy or Sell Amgen Stock Ahead of Its Earnings?
Published: August 04, 2025 by: Forbes
Sentiment: Negative
Amgen (NASDAQ:AMGN) is set to release its earnings on Tuesday, August 5, 2025. Historically, Amgen's stock has shown a tendency to experience negative one-day returns following its earnings announcements.
Read More
Gear Up for Amgen (AMGN) Q2 Earnings: Wall Street Estimates for Key Metrics
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Read More
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.
Read More
Amgen (AMGN) Just Flashed Golden Cross Signal: Do You Buy?
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen Inc. (AMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AMGN's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Read More
5 Dogs of the Dow Are Crushing the S&P 500 and Nasdaq in 2025
Published: July 28, 2025 by: 24/7 Wall Street
Sentiment: Neutral
The Dogs of the Dow is a well-known strategy first published in 1991 by Michael O'Higgins.
Read More
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.
Read More
NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership Team Will spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolio Brings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Dr. Jyothis George, M.D., Ph.D., …
Read More
Undercovered Dozen: Christian Dior, Coca-Cola, Trinity Capital, Amgen And More
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Neutral
This week's Undercovered Dozen spotlights 12 lesser-known stocks with compelling investment theses, spanning micro-nuclear, luxury, biotech, and high-yield BDCs. Highlighted opportunities include NANO Nuclear Energy's niche potential, Christian Dior SE's LVMH exposure, and Harrow's explosive growth in ophthalmic pharmaceuticals. Coca-Cola and Ares Capital are flagged as overvalued or increasingly risky, with warnings of unsustainable growth and looming corrections for investors.
Read More
Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive?
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
What Makes Amgen (AMGN) a New Buy Stock
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Are Medical Stocks Lagging Amgen (AMGN) This Year?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Amgen (AMGN) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Read More
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Amgen (AMGN) is a Top-Ranked Growth Stock: Should You Buy?
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Amgen (AMGN) Outperforms Broader Market: What You Need to Know
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The latest trading day saw Amgen (AMGN) settling at $296.85, representing a +2.18% change from its previous close.
Read More
About Amgen Inc. (AMGN)
- IPO Date 1983-06-17
- Website https://www.amgen.com
- Industry Drug Manufacturers - General
- CEO Robert A. Bradway
- Employees 28000